News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Strikes Pact With Regenerex LLC to Boost Cell Therapy Portfolio


9/6/2013 8:14:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN) entered a collaboration with Regenerex LLC, gaining access to stem cell technology that may help kidney transplant patients avoid taking anti-rejection medicine for life. Regenerex, a startup biology company based in Louisville, Kentucky, and Novartis have entered an exclusive global licensing deal and will work together on research, the Basel, Switzerland-based company said in an e-mailed statement today. Regenerex’s technology allowed five of eight kidney transplant patients to stop taking about a dozen pills a day to suppress their immune systems, according to research published last year.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES